Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr Reddy's Proprietary Products Gain US Traction Amid Tough Q2

Executive Summary

Early traction for its differentiated neurology and dermatology formulations in the US and signs of ebbing volatility in emerging markets bode well for Dr Reddy's Laboratories, amid a sharp decline in second quarter profits on a year-on-year basis. Investors also have their eyes firmly set on progress of the firm's key generic opportunities for Copaxone, Aloxi and Gleevec in the US.

You may also be interested in...



Chinese Stamp On Indian Pharma; All Eyes On Regulatory Flow

The Fosun group led by its billionaire chair Guo Guangchang has snapped up the injectables firm Gland for around $1.26bn, the first mega Chinese buy in the Indian pharmaceutical space. The deal opens up many potential collaborative opportunities, though it remains to be seen how smoothly it sails through in the Indian regulatory maze.

Dr Reddy's Slumps In Q1 But Will Pressures Ease Soon?

Dr. Reddy’s Laboratories (DRL) has reported a slump in profits for the first quarter, dented by a decline in volume growth and pricing pressure in the US as well as a loss of business in Venezuela. While the firm's long term story appears intact, resolution of compliance issues at its Indian sites and product flows in the US and other markets (DRL expects to participate in a Russian tender for rituximab) could lift investor sentiment significantly.

Dr. Reddy’s Warns Over Currency Effects As Emerging Markets Slide

Indian generic drug giant Dr. Reddy’s says the crash of currencies in some emerging markets may impact earnings as it reported a tough third-quarter in which net profit was sharply below market expectations.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel